SRZN

Rating neutralTentativeAI Memo

Surrozen

As of 2026-09-24/Confidence medium

Open ticker Back to Memos

Data freshness

AI Memo

As of 2026-09-24 • Model: RankAlpha Sentiment Codex

Decision Panel

Action, confidence, horizon, and decision blockers at a glance.

Report quality notice

small-cap biotech peer set is too weak or includes unrelated comparators for a standard-conviction report

Action

neutral

Confidence

medium

Horizon

—

Key catalyst

DUET study initiation • 2026-12-31

Base target: $18 / p=45% prob

Biggest risk

DUET has not yet begun, clinical efficacy is unproven, and development spending may rise. June-quarter net income included $59.6 million of non-cash liability remeasurement gains and should not be read as recurring operating profitability. [#SEC-8K-2026-08-06] https://surrozen.com/press_releases/surrozen-reports-second-quarter-2026-financial-results-and-provides-business-update/

Invalidation

Break below $8 or thesis failure.

What would change my mind?

The early IND submission supports execution, while DUET offers a defined path to initial clinical evidence. The June-quarter release reported $102.0 million in cash and a $5.0 million collaboration milestone. [#SEC-8K-2026-08-06] [#IR-2026-09-08] https://surrozen.com/press_releases/surrozen-reports-second-quarter-2026-financial-results-and-provides-business-update/

Research note

Recommendation

neutral

Confidence

medium

As of

2026-09-24

Base target

$18

p=45%

Bull target

$27

p=25%

Bear target

p=30%

Key bullets

Fast scan of bull, bear, and watch items

BullKey bullets

Initial DUET clinical data
The early IND submission supports execution, while DUET offers a defined path to initial clinical evidence.
The June-quarter release reported $102.0 million in cash and a $5.0 million collaboration milestone.

BearKey bullets

Early-stage safety or efficacy results may fail to support differentiation from established retinal therapies.
Regulatory or operational delays could postpone DUET initiation beyond management's year-end 2026 expectation.
Reported quarterly profit was dominated by non-cash liability remeasurement gains rather than recurring operations.

WatchKey bullets

DUET study initiation

Summary

High-level snapshot

Recommendation

neutral

Model confidence

medium

Timeframe

Asset

Equity

Trigger

Base case: $18 (p=45%)

Target spread vs base: +50% / -56%

Scenario probabilities

Bull Target: $27 (p=25%)Base Target: $18 (p=45%)Bear Target: $8 (p=30%)

Commentary

The September 8 IND submission is a genuine positive update to the prior baseline, which still treated submission as pending. The packet contains no verified analyst revisions, attributable post-announcement price reaction, or sufficient social sample; zero-valued sentiment fields indicate unavailable measurements, not observed neutrality. Low independent coverage and unconfirmed study initiation warrant monitoring rather than a stronger rating. [#IR-2026-09-08] https://surrozen.com/press_releases/surrozen-announces-submission-of-ind-application-for-szn-8141-for-the-treatment-of-diabetic-macular-edema/

As of 2026-09-24 • Updated bi-weekly / post-earningsSource: Internal modelMethodology

Analyst Summary

Thesis highlights from the latest analysis

Bull Case

Bear Case

Drivers

Scannable catalysts and supporting factors

Initial DUET clinical data

Scenarios

Bull Target (Scenario probability)

$27 / p=25% prob

Base Target (Scenario probability)

$18 / p=45% prob

Bear Target (Scenario probability)

$8 / p=30% prob

Analysis 2026-09-24 · RankAlpha Sentiment Codex

Analysis reference price unavailable. Targets are shown without scenario returns.

Sentiment & Exposure

News Sentiment (30d)

0.20

Social Sentiment (7d)

0.00

Events

Other notable items detected

EVENT2026-12-31
DUET study initiation
Surrozen submitted the SZN-8141 IND on September 8 and still expects to initiate the Phase 1b/2a DUET study in diabetic macular edema by year-end. Submission removes the prior filing milestone, but study initiation remains unconfirmed. [#8-K-2026-08-06] [#IR-2026-09-08] https://surrozen.com/press_releases/surrozen-announces-submission-of-ind-application-for-szn-8141-for-the-treatment-of-diabetic-macular-edema/
Prob 65.00% • Move 15.00% • Priced-in 50.00%

Short-term Catalysts

Next few weeks

No short-term catalysts

Long-term Catalysts

Months to a year

Initial DUET clinical data
2027-12-31
Initial data are anticipated in the second half of 2027. Safety and early activity could test the investment case, but preclinical findings do not establish clinical benefit. [#SEC-8K-2026-08-06] [#IR-2026-09-08] https://surrozen.com/press_releases/surrozen-announces-submission-of-ind-application-for-szn-8141-for-the-treatment-of-diabetic-macular-edema/
Prob 45% • Move 45% • Priced-in 20%

Risks

Early-stage safety or efficacy results may fail to support differentiation from established retinal therapies.
Regulatory or operational delays could postpone DUET initiation beyond management's year-end 2026 expectation.
Reported quarterly profit was dominated by non-cash liability remeasurement gains rather than recurring operations.
Rising R&D costs and future trial funding needs create dilution risk despite the reported June 30 cash balance. [#SEC-8K-2026-08-06]

Peers

Symbol	Summary
EYPT	EyePoint has studied intravitreal DURAVYU in Phase 2 diabetic macular edema, making it an indication-level comparator. Its delivery approach and more advanced clinical evidence differ from Surrozen's pre-DUET SZN-8141 program; it is not a direct valuation multiple. https://investors.eyepointpharma.com/static-files/b5b4deb1-5974-4783-a175-9d46de992991
KOD	Kodiak Sciences is a direct diabetic-macular-edema development comparator: its VEGF/IL-6-targeting KSI-501 entered a Phase 3 DME study in 2026. Its later clinical stage and different mechanism limit valuation comparability. https://ir.kodiak.com/news-releases/news-release-details/kodiak-sciences-announces-first-patients-enrolled-global-phase-3

Sources

Internal and external references used in this analysis

Model source: RankAlpha Sentiment Codex
Analysis date: 2026-09-24

Loading AI feed…

Symbol

Summary

EYPT

EyePoint has studied intravitreal DURAVYU in Phase 2 diabetic macular edema, making it an indication-level comparator. Its delivery approach and more advanced clinical evidence differ from Surrozen's pre-DUET SZN-8141 program; it is not a direct valuation multiple. https://investors.eyepointpharma.com/static-files/b5b4deb1-5974-4783-a175-9d46de992991

KOD

Kodiak Sciences is a direct diabetic-macular-edema development comparator: its VEGF/IL-6-targeting KSI-501 entered a Phase 3 DME study in 2026. Its later clinical stage and different mechanism limit valuation comparability. https://ir.kodiak.com/news-releases/news-release-details/kodiak-sciences-announces-first-patients-enrolled-global-phase-3